November 8, 2019

The Week’s Biggest Winner & Loser

Kohl’s (KSS)

For a discount clothier like Kohl’s (KSS) which gets all its product from China, any good Trade War news is good news. That showed this week as KSS rocketed +9.50% following positive trade tips, earning itself the week’s Biggest Winner spot.

GW Pharma (GWPH)

Despite a blowout quarter, GW Pharmaceuticals (GWPH) got positively slammed under growth concerns, dropping a hideous -19.74% and earning itself the not-so-coveted spot of Biggest Loser (possibly biggest loser ever).

Portfolio Allocation

Click charts for enlarged versions



Target Position Size

Portfolio Breakdown

Year-to-Date Performance

Current Position Performance

Boeing (BA)


1st Buy 2/14/2012 @ $79.58
Current Per-Share: (-$1,053.52)*

Nvidia (NVDA)


1st Buy 9/6/2016 @ $63.10
Current Per-Share: $29.42

Apple (AAPL)


1st Buy 4/18/2013 @ $56.38
Current Per-Share: (-$112.44)*

Square (SQ)


1st Buy 8/5/2016 @ $11.10
Current Per-Share: (-$40.61)*

Nike (NKE)


1st Buy 2/14/2012 @ $26.71
Current Per-Share: (-$43.25)*

Disney (DIS)


1st Buy 2/14/2012 @ $41.70
Current Per-Share: (-$6.07)*



1st Buy 7/26/2017 @ $167.29
Current Per-Share: $99.50

JP Morgan (JPM)


1st Buy 10/26/2017 @ $102.30
Current Per-Share: $97.18

Salesforce (CRM)


1st Buy 6/11/2018 @ $134.05
Current Per-Share: $120.10

Citigroup (C)


1st Buy 10/26/2017 @ $74.06
Current Per-Share: $57.50

Take Two (TTWO)


1st Buy 7/30/2018 @ $120.99
Current Per-Share: $89.83

Logitech (LOGI)


1st Buy 11/11/2016 @ $24.20
Current Per-Share: $32.52



1st Buy 11/6/2018 @ $120.87
Current Per-Share: $109.24

Kohl’s (KSS)


1st Buy 6/3/2019 @ $50.45
Current Per-Share: $47.49

Dow (DOW)


1st Buy 5/13/2019 @ $53.18
Current Per-Share: $47.75

FedEx (FDX)


1st Buy 9/18/2019 @ $152.59
Current Per-Share: $145.49

Amazon (AMZN)


1st Buy 2/6/2018 @ $1,378.96
Current Per-Share: $1,615.85

Berkshire (BRK.B)


1st Buy 8/2/2019 @ $201.96
Current Per-Share: $201.96

Canopy (CGC)


1st Buy 5/24/2018 @ $29.53
Current Per-Share: $19.69

Cisco (CSCO)


1st Buy 8/23/2019 @ $47.60
Current Per-Share: $47.24

Pfizer (PFE)


1st Buy 1/28/2019 @ $40.50
Current Per-Share: $38.54

Xilinx (XLNX)


1st Buy 5/13/2019 @ $111.57
Current Per-Share: $102.57

GW Pharm (GWPH)


1st Buy 7/25/2018 @ $142.28
Current Per-Share: $123.16

Twilio (TWLO)


1st Buy 8/8/2019 @ $125.71
Current Per-Share: $107.61

* Indicates a position where the capital investment was sold.
Profit % for * positions = Total Profit / Original Capital Investment

This Week’s Moves

Citigroup (C): Profit-Taking

Citigroup (C) continued higher on Monday, crossing a key level and triggering a trailing stop sell order I had placed at $75.24 which filled when Citigroup pulled back to the $75.21.

Citigroup is incredibly volatile thanks to its exposure to the international banking sector, so taking advantage of its wide price swings over time has been a key technique for me to capitalize on this long-term position.

Monday’s sale lowered my per-share cost -1.46% from $58.35 to $57.50. My next sell target is near $80.00 and my buy target is $53.25, quite the spread.

C closed the week at $76.12, up +1.21% from where I sold on Monday.

FedEx (FDX): Profit-Taking

While I do intend to build a position in the company for the long-term, FedEx’s (FDX) incredible bounce from $137.78 in excess of +20% in less than a month has been an inexplicable marvel to behold, however, it also means it’s time to take profits to reduce my per-share cost if FDX rolls over again.

On Tuesday, FedEx broke through $166 where I placed a trailing stop order to take profits which filled when FDX hit a high of $167.59 and pulled back, filling at $166.78 per share.

The sale reduced my per-share cost -4.65% from $152.59 to $145.49.

From here, I have no additional sell targets (this is a long-term investment), with my next buy target at $138.85, slightly above its $137.78 low set in October.

FDX closed the week at $163.22, down -2.13% from where I sold on Tuesday. 

GW Pharmaceuticals (GWPH): Added to Position

GW Pharmaceuticals (GWPH) dropped more than -16% on Wednesday after reporting an excellent blowout quarter Tuesday after the bell. 

What the heck happened?!!

GWPH is a biopharmaceutical stock whose primary drug – Epidiolex for epilepsy in children – is selling like hotcakes internationally. However, many analysts are concerned that the company’s forecasts for the sales growth of the drug are exaggerated, causing the stock to sell off.

Personally, I see a great deal of potential in GWPH for the long term. While it is using cannabis to produce its drugs, these are prescription-strength pharmaceutical-grade products, not CBD oil or marijuana cigarettes.

When GWPH crashed through $110 on Wednesday, I used a trailing stop order to add to my position, filling at $109.12. The buy reduced my per-share cost -2.77% from $126.67 to $123.16. My next buy target is $92.25 with some profit-taking possible if GWPH works its way over $140 in the coming weeks.

GWPH closed the week at $109.41, up +0.27% from my Wednesday buy.

Square (SQ): Profit-Taking

Square (SQ) popped on Thursday after reporting decent earnings Wednesday after-the-bell. I set a trailing stop order which I hoped would fill at $65.06 and Square’s price action was so bullish, my order ended up filling at $66.32, a gain of 1.94% over my desired target.

The sale captured gains of 16.29% on some more of the shares I bought less than two months ago on September 16 for $57.03. My next sell target is around $70.00 (I have a trailing stop order set to start at $69.54 with a $0.10 trail).

Currently, I have no plans to add to my Square position as it is quite overweight in my portfolio, however, I would target the $55-60 range for additional buys if I was going to add more.

SQ closed the week at $62.45, down -5.84% from where I sold on Thursday.

Take Two Interactive (TTWO): Profit-Taking

Take Two Interactive (TTWO), the video game maker behind Grand Theft Auto, Red Dead Redemption, and Borderlands, reported a good quarter but gave poor guidance on Thursday after the bell.

The stock showed such poor price action during after-hours trading that I nearly closed my entire position, but Friday morning, TTWO started rising significantly. I capitalized on the opportunity to take profits on some shares using trailing stop orders that yielded an average selling price of $120.90.

The sale lowered my per-share cost -7.96% from $97.60 to $89.83. My buy target for TTWO is $91.85 and my next sell target is $134-135.

TTWO closed the week at $116.96, down -3.26% from my average selling price.

Twilio (TWLO): Added to Position

Twilio (TWLO) sold off substantially last week following a bad earnings report combined with “accounting issues.” This week, Twilio’s CEO told Jim Cramer on CNBC’s Mad Money mid-week that the error was made in the press release – the mistake showed better earnings than actual, however, the positive long-term forecast remained unchanged.

On Thursday, TWLO appeared to find support around $91.00 where I placed a small trailing stop order that filled at $90.96. The buy lowered my per-share cost -1.18% from $108.89 to $107.61.

My next buy order will place if TWLO breaks through its recent low of $89.84.

 TWLO closed the week at $93.23, up +2.50% from where I added Thursday.

Want Further Clarification?

As always, if you have questions about any of my positions or have positions of your own that you’re curious about – feel free to leave a comment below!

See you next week!

Don't get mad, Get Irked and learn how to invest for yourself!


Get Irked is a small community made up of helpful, friendly and motivated investors and traders of all levels looking to reach the same goal – the ability to invest profitably in order to achieve financial independence.

Investors of ALL experience levels are welcome.

Join Get Irked by clicking here!

Eric “Irk” Jacobson and all other Get Irked contributors are not investment or financial advisers. All strategies, trading ideas, and other information presented comes from non-professional, amateur investors and traders sharing techniques and ideas for general information purposes.

As always, all individuals should consult their financial advisers to determine if an investing idea is right for them. All investing comes with levels of risk with some ideas and strategies carrying more risk than others.

As an individual investor, you are accountable for assessing all risk to determine if the strategy or idea fits with your investment style. All information on Get Irked is presented for educational and informational purposes only.